Hansa Biopharma announces participation in Fall conferences and an updated financial calendar

Hansa Biopharma has been invited to participate in several leading global healthcare conferences during the Fall 2020. 
Hansa Biopharma will host a Capital Markets Day event on October 29, 2020 in Copenhagen as a combined virtual/physical setup. 

Lund, Sweden August 31, 2020. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company’s management team will present at the following upcoming investor conferences in September:

• Pareto Securities Health Care Conference on Thursday September 3, 2020, at 15:30 CET
• Citibank’s Annual BioPharma Virtual Conference on Wednesday September 9, 2020 
• H.C.Wainwrigth Healthcare Conference on Tuesday September 15, 2020 
• Bank of America Merill Lynch Healthcare Conference on Wednesday September 16, 2020
• MorganStanley Global Healthcare Conference on Friday September 18, 2020 at 8:00am EST/14:00 CET
• ABG Small & Midcap Seminar, Copenhagen on Wednesday September 23, 2020 at 13:30 CET

A link to the presentations and webcasts will be available on the Events & Presentations page of the Company's website at http://www.hansabiopharma.com.

Calendar
Aug 31,2020       Kempen Road Show, Tel Aviv/Paris/Benelux (virtual)
Sep 3, 2020        Pareto Healthcare Conference, Stockholm (virtual)
Sep 9, 2020        Citibank’s Annual BioPharma Virtual Conference, Boston (virtual)
Sep 15, 2020      H.C. Wainwright Healthcare Conference, NYC (virtual)
Sep 16, 2020      Bank of America Merill Lynch Healthcare Conf., London (virtual)
Sep 18, 2020      MorganStanley Global Healthcare Conference, NYC (virtual)
Sep 23, 2020      ABG Small & Mid Cap Seminar, Copenhagen and virtual
Oct 22, 2020       Interim Report Jan-Sep 2020
Oct 29, 2020       Hansa Biopharma Capital Markets Day, Copenhagen and virtual
Nov 17, 2020      Bryan Garnier Healthcare Conference, Paris
Nov 18, 2020      Jefferies Healthcare Conference, London
Nov 25, 2020      Ökonomisk Ugebrev Life Science Conference, Copenhagen
Feb 2, 2021        Interim report for Jan - Dec 2020
April 8, 2021       Annual Report 2020
April 22, 2021     Interim report for Jan - Mar 2021
July 15, 2021      Interim report for Jan - Jun 2021
Oct 21, 2021       Interim report for Jan – Sep 2021

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa’s research and development program is advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.